Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77

CytomX Therapeutics, Inc. (NASDAQ:CTMX) has earned an average rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $5.77.

Separately, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a research note on Monday, November 11th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CTMX. Jacobs Levy Equity Management Inc. boosted its position in shares of CytomX Therapeutics by 1.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock worth $1,798,000 after buying an additional 16,359 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in CytomX Therapeutics by 10.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock valued at $331,000 after acquiring an additional 26,373 shares in the last quarter. US Bancorp DE acquired a new position in CytomX Therapeutics during the 3rd quarter worth $40,000. Geode Capital Management LLC grew its stake in shares of CytomX Therapeutics by 4.4% in the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock worth $948,000 after purchasing an additional 34,032 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in shares of CytomX Therapeutics by 1.4% during the second quarter. Acadian Asset Management LLC now owns 2,728,569 shares of the biotechnology company’s stock valued at $3,324,000 after purchasing an additional 37,739 shares during the period. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Trading Down 1.8 %

CTMX stock opened at $1.07 on Friday. The stock’s 50 day simple moving average is $1.06 and its 200 day simple moving average is $1.20. CytomX Therapeutics has a 12-month low of $0.83 and a 12-month high of $5.85. The firm has a market cap of $83.74 million, a P/E ratio of 6.29 and a beta of 1.07.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The company had revenue of $33.43 million for the quarter, compared to analysts’ expectations of $18.92 million. During the same period in the prior year, the company earned $0.04 earnings per share. On average, research analysts forecast that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.